ReviewPharmaceuticals (Basel, Switzerland)2022
Insulin Resistance and Acne: The Role of Metformin as Alternative Therapy in Men.
Review in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Pooled it
- Review
- Evaluation of the Efficacy of Metformin in the Treatment of Acne Vulgaris and Its Effects on Serum Lipid Metabolism.Journal of cosmetic dermatology · 2025Article
- Differential plasma proteome analysis reveals key proteins associated with insulin resistance in acne vulgaris patients.Scientific reports · 2025Article
- New Perspectives on Nutraceutical Insulin Sensitizing Agents in the Treatment of Psoriasis and Other Dermatological Diseases.International journal of molecular sciences · 2025Review
- Multifactorial Refractory Acne in Women: Insights from a Case Series Involving Hormonal-, Metabolic-, and Corticosteroid-Related Triggers.Life (Basel, Switzerland) · 2025Article
- Off-Label Treatment in Inflammatory Skin Diseases-European Point of View.Journal of clinical medicine · 2025Review
- Skin Microbiota: Mediator of Interactions Between Metabolic Disorders and Cutaneous Health and Disease.Microorganisms · 2025Review
- Advances in the treatment of glioma-related signaling pathways and mechanisms by metformin.Frontiers in oncology · 2025Review
- Treatment of insulin resistance with tirzepatide leading to improvement of hair loss.JAAD case reports · 2024Article
- Metformin Therapy for Acne Vulgaris: A Meta-Analysis.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Review
- Potential for NPY receptor-related therapies for polycystic ovary syndrome: an updated review.Hormones (Athens, Greece) · 2023Review
- Insulin Resistance in Patients with Acne Vulgaris.Biomedicines · 2023Article
- Impact on Glycemic Variation Caused by a Change in the Dietary Intake Sequence.Foods (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The association between acne and insulin resistance has not been investigated as thoroughly in males as it has been in women, despite the fact that in adult men, acne prevalence has grown. On the face, sebaceous glands produce and secrete sebum, which lubricates the skin and protects it from friction. Metformin, an insulin-sensitizing medication, may modify the association between acne vulgaris and insulin resistance (IR). Individuals with IR, metabolic syndrome or with impaired glucose tolerance are sometimes treated 'off label' with Metformin. In these conditions, IR may be a leading factor in the pathogenesis of acne, and in men, Metformin treatment may reduce the Global Acne Grading System (GAGS) score by enhancing insulin sensitivity. However, additional clinical studies are required to corroborate these assumptions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.